Added to YB: 2026-05-12
Pitch date: 2026-05-10
BDTX [neutral]
Black Diamond Therapeutics, Inc.
-3.29%
current return
Author Info
No bio for this author
Company Info
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
Market Cap
$155.8M
Pitch Price
$3.04
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.16
P/E
-3.59
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Q1 Earnings Wire May 8, 2026 PM Drop - Black Diamond Therapeutics, Inc.
BDTX (earnings): Q1 loss $9M, R&D $7M post-BDTX-4933 outlicense. $118.3M cash, runway to 2H 2028. Silevertinib Phase 2 frontline EGFRm NSCLC data (DOR/PFS) at ASCO May 30. First patient dosed in Phase 2 silevertinib+TMZ for EGFRvIII+ GBM. Cleanest sub-$200M EGFRm name, ASCO in 3wks is catalyst.
Read full article (1 min)